FDA OCP Seeks Public Input on Drug Development Clinical Pharmacology Programs

The FDA is soliciting input from interested parties on policy topics the CDER Office of Clinical Pharmacology (OCP) could develop and implement to support drug development programs.
Source: Drug Industry Daily